产品编号 :
Cas No. :
CAS No. |
2070009-58-2 |
|---|---|
中文名称 |
雷伏塞替尼盐酸盐 |
英文名称 |
Ravoxertinib HCl |
别名 |
GDC-0994 (hydrochloride);GDC-0994 HCl;CS-2072;Ravoxertinib hydrochloride;RAVOXERTINIB HYDROCHLORIDE (GDC-0994 HYDROCHLORIDE);Ravoxertinib hydrochloride (GDC-0994 |
标准英文名 |
(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one hydrochloride |
MDL No. |
MFCD29472257 |
分子式 |
C21H19Cl2FN6O2 |
分子量 |
477.33 |
精确分子量 |
476.09 |
SMILES |
O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO.[H]Cl |
标准SMILES |
Cl.CN1N=CC=C1NC1N=C(C=CN=1)C1C=CN([C@H](CO)C2C=C(F)C(Cl)=CC=2)C(=O)C=1 |
用途 |
Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally available ERK inhibitor used for the treatment of cancers, particularly those driven by KRAS or BRAF mutations; it demonstrates significant single-agent antitumor activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. |
InChIKey |
RMNVBUVHPAETTJ-GMUIIQOCSA-N |
|
|
评论 |
|---|